Related Experiment Video
Updated: Feb 20, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.5K
Heparosan-coated liposomes for drug delivery
Rachel S Lane1, F Michael Haller2, Anais A E Chavaroche2
1Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126, USA.
Glycobiology
|October 19, 2017
Summary
Heparosan (HEP) coating on liposomes may offer an alternative to polyethylene glycol (PEG) for cancer drug delivery. This novel coating shows potential for improved circulation and reduced immune response, enhancing chemotherapy effectiveness.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Immunology
Background:
- Liposomal encapsulation, exemplified by Doxil®, enhances chemotherapy delivery to tumors.
- Polyethylene glycol (PEG) coating on liposomes improves circulation but can elicit anti-PEG immune responses, limiting efficacy.
- Alternative coatings are needed to overcome PEG-induced immunogenicity and improve drug delivery outcomes.
Purpose of the Study:
- To investigate heparosan (HEP) as a potential alternative coating for liposomes, replacing PEG.
- To evaluate the ability of HEP-coated liposomes to evade the mononuclear phagocyte system (MPS) and prolong circulation time.
- To compare the immunogenicity and anti-cancer efficacy of HEP-coated liposomes versus PEG-coated liposomes.
Main Methods:
- Characterization of HEP-lipid insertion into liposomes using dynamic light scattering and coarse-grain computer modeling.
- Assessment of HEP-lipid immunogenicity in a rat model.
- Comparative efficacy study of HEP-coated versus PEG-coated doxorubicin liposomes in a human breast cancer xenograft mouse model.
Main Results:
- Heparosans (HEP) were successfully incorporated into liposomes, demonstrating potential as a PEG alternative.
- Initial studies suggest HEP-coated liposomes may evade immune detection, prolonging circulation.
- Comparative efficacy studies are underway to determine if HEP-coated liposomes improve drug delivery and anti-tumor activity.
Conclusions:
- Heparosans (HEP) present a promising alternative to polyethylene glycol (PEG) for liposome coating in drug delivery.
- HEP-coated liposomes may overcome limitations associated with PEG immunogenicity, potentially improving therapeutic outcomes.
- Further research is warranted to fully elucidate the clinical potential of HEP-based liposomal drug delivery systems.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
34
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
34
01:11Oral Drug Delivery Systems: Delayed-Release Systems
42
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
42
01:27Bioavailability Enhancement: Drug Permeability Enhancement
223
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
223
01:24Modified-Release Drug Delivery Systems: Site-Targeted
30
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
30
00:59COP Coated Vesicles
18.3K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
18.3K
01:19Modified-Release Drug Delivery Systems: Overview
31
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
31